232 related articles for article (PubMed ID: 25801032)
41. Hematopoietic Stem Cell Activity Is Regulated by Pten Phosphorylation Through a Niche-Dependent Mechanism.
Li J; Zhang J; Tang M; Xin J; Xu Y; Volk A; Hao C; Hu C; Sun J; Wei W; Cao Q; Breslin P; Zhang J
Stem Cells; 2016 Aug; 34(8):2130-44. PubMed ID: 27096933
[TBL] [Abstract][Full Text] [Related]
42. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
43. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
Nozhat Z; Hedayati M
Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
[TBL] [Abstract][Full Text] [Related]
44. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
Zuurbier L; Petricoin EF; Vuerhard MJ; Calvert V; Kooi C; Buijs-Gladdines JG; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Pieters R; Meijerink JP
Haematologica; 2012 Sep; 97(9):1405-13. PubMed ID: 22491738
[TBL] [Abstract][Full Text] [Related]
45. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
46. (‑)‑Epigallocatechin‑3‑gallate induces apoptosis in human pancreatic cancer cells via PTEN.
Liu S; Xu ZL; Sun L; Liu Y; Li CC; Li HM; Zhang W; Li CJ; Qin W
Mol Med Rep; 2016 Jul; 14(1):599-605. PubMed ID: 27176210
[TBL] [Abstract][Full Text] [Related]
47. Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling.
Foster JS; Fish LM; Phipps JE; Bruker CT; Lewis JM; Bell JL; Solomon A; Kestler DP
BMC Cancer; 2013 May; 13():227. PubMed ID: 23648148
[TBL] [Abstract][Full Text] [Related]
48. PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN.
Li B; Smith TJ
J Clin Endocrinol Metab; 2014 Sep; 99(9):3363-72. PubMed ID: 24840811
[TBL] [Abstract][Full Text] [Related]
49. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
50. Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL cells in vitro.
Calzavara E; Chiaramonte R; Cesana D; Basile A; Sherbet GV; Comi P
J Cell Biochem; 2008 Apr; 103(5):1405-12. PubMed ID: 17849443
[TBL] [Abstract][Full Text] [Related]
51. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
52. Desmethylanhydroicaritin inhibits NF-kappaB-regulated inflammatory gene expression by modulating the redox-sensitive PI3K/PTEN/Akt pathway.
Kim JH; Lee G; Cho YL; Kim CK; Han S; Lee H; Choi JS; Choe J; Won MH; Kwon YG; Ha KS; Kim YM
Eur J Pharmacol; 2009 Jan; 602(2-3):422-31. PubMed ID: 19027002
[TBL] [Abstract][Full Text] [Related]
53. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
Palomero T; Sulis ML; Cortina M; Real PJ; Barnes K; Ciofani M; Caparros E; Buteau J; Brown K; Perkins SL; Bhagat G; Agarwal AM; Basso G; Castillo M; Nagase S; Cordon-Cardo C; Parsons R; Zúñiga-Pflücker JC; Dominguez M; Ferrando AA
Nat Med; 2007 Oct; 13(10):1203-10. PubMed ID: 17873882
[TBL] [Abstract][Full Text] [Related]
54. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
55. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
Bi X; Lv X; Liu D; Guo H; Yao G; Wang L; Liang X; Yang Y
Cancer Gene Ther; 2021 Apr; 28(3-4):335-349. PubMed ID: 32939058
[TBL] [Abstract][Full Text] [Related]
56. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
Haddadi N; Lin Y; Travis G; Simpson AM; Nassif NT; McGowan EM
Mol Cancer; 2018 Feb; 17(1):37. PubMed ID: 29455665
[TBL] [Abstract][Full Text] [Related]
57. Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes.
Wilhelm F; Kässner F; Schmid G; Kratzsch J; Laner A; Wabitsch M; Körner A; Kiess W; Garten A
Growth Horm IGF Res; 2015 Jun; 25(3):115-20. PubMed ID: 25900365
[TBL] [Abstract][Full Text] [Related]
58. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
[TBL] [Abstract][Full Text] [Related]
59. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway.
Tian T; Nan KJ; Guo H; Wang WJ; Ruan ZP; Wang SH; Liang X; Lu CX
Oncol Rep; 2010 Jun; 23(6):1593-600. PubMed ID: 20428814
[TBL] [Abstract][Full Text] [Related]
60. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
